FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297997373> ?p ?o ?g. }

• W4297997373 abstract "Objective: After Gemstone-302 was published in Lancet in January 2022, seven PD-(L)1 inhibitors launched or about to be launched in China, but there are no head-to-head RCTs reporting the comparative efficacy for squamous non-small cell lung cancer (sq-NSCLC). Therefore, we aimed to indirectly compare the efficacy of these treatments to provide evidence for clinical decision and Chinese national reimbursement drug listing. Methods: We collected phase III clinical trials targeted on stage IIIB-IV patients for first-line immunotherapy of sq-NSCLC by systematically searching databases. Relative effects of competing treatments were assessed by Bayesian network meta-analysis and non-parametric restricted mean survival time (RMST) model. Hazard ratio (HR), severe adverse events (SAEs, grade 3-5), progression-free survival (PFS) and overall survival (OS) years were the outcomes. Subgroup analysis was done according to PD-(L)1 expression, smoking, gender, Eastern Cooperative Oncology Group performance status, age and disease stage. Sensitivity analysis using the range of parameters distribution as well as different comparison methods was performed to test the robustness of the results. Results: A total of 7 clinical trials with 2,640 patients were included. For OS, the efficiency (HR, 95%CI) ranks from high to low were sugemalimab (0.48, 0.32-0.73), camrelizumab (0.55, 0.40-0.76), sintilimab (0.56, 0.35-0.90), pembrolizumab (0.71, 0.58-0.87) and atezolizumab (0.88, 0.73-1.05). For PFS, the efficiency ranks from high to low were sugemalimab (0.33, 0.24-0.45), camrelizumab (0.37, 0.30-0.46), tislelizumab (0.53, 0.36-0.79), sintilimab (0.54, 0.42-0.69), toripalimab (0.56, 0.38-0.83), pembrolizumab (0.57, 0.47-0.70) and atezolizumab (0.71, 0.59-0.85). Proportional hazard models and non-proportional hazard models showed consistent efficiency ranks. When extrapolated to long-term survival benefit, under non-proportional hazard ratio, sugemalimab achieved the highest PFS benefit (lifeyears, LYs) in 2 years (1.323), with camrelizumab (1.320), sintilimab (1.243), tislelizumab (1.189), pembrolizumab (0.990) and atezolizumab (0.947) ranking in order; Camrelizumab achieved the highest OS benefit (LYs) in 10 years (2.723), with atezolizumab (2.445) and pembrolizumab (2.397) ranking in order. RMST model showed similar results. In terms of safety, PD-(L)1 inhibitors increased the incidence of SAEs when combined with chemotherapy, sugemalimab and camrelizumab was the safest drugs. Conclusion: Sugemalimab is superior both in HR and long-term survival benefit for Chinese patients with advanced sq-NSCLC." @default.
• W4297997373 created "2022-10-01" @default.
• W4297997373 creator A5006864304 @default.
• W4297997373 creator A5024628268 @default.
• W4297997373 creator A5037377894 @default.
• W4297997373 creator A5079920224 @default.
• W4297997373 creator A5012929424 @default.
• W4297997373 date "2022-09-29" @default.
• W4297997373 modified "2023-09-30" @default.
• W4297997373 title "Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis" @default.
• W4297997373 cites W1950618346 @default.
• W4297997373 cites W1982967337 @default.
• W4297997373 cites W2037139573 @default.
• W4297997373 cites W2038934354 @default.
• W4297997373 cites W2059573268 @default.
• W4297997373 cites W2063490878 @default.
• W4297997373 cites W2086632345 @default.
• W4297997373 cites W2096322385 @default.
• W4297997373 cites W2099725888 @default.
• W4297997373 cites W2122495232 @default.
• W4297997373 cites W2138234714 @default.
• W4297997373 cites W2146014573 @default.
• W4297997373 cites W2167191456 @default.
• W4297997373 cites W2169205464 @default.
• W4297997373 cites W2228221433 @default.
• W4297997373 cites W2560367415 @default.
• W4297997373 cites W2595504958 @default.
• W4297997373 cites W2765620715 @default.
• W4297997373 cites W2776959966 @default.
• W4297997373 cites W2892640821 @default.
• W4297997373 cites W2900623060 @default.
• W4297997373 cites W2935577863 @default.
• W4297997373 cites W2938144346 @default.
• W4297997373 cites W2946950110 @default.
• W4297997373 cites W2964471257 @default.
• W4297997373 cites W3015859409 @default.
• W4297997373 cites W3017322331 @default.
• W4297997373 cites W3037506839 @default.
• W4297997373 cites W3045365702 @default.
• W4297997373 cites W3119125273 @default.
• W4297997373 cites W3128646645 @default.
• W4297997373 cites W3128901804 @default.
• W4297997373 cites W3144903047 @default.
• W4297997373 cites W3145993063 @default.
• W4297997373 cites W3149883437 @default.
• W4297997373 cites W3165007730 @default.
• W4297997373 cites W3166329536 @default.
• W4297997373 cites W3197108615 @default.
• W4297997373 cites W3207353954 @default.
• W4297997373 cites W3207969153 @default.
• W4297997373 cites W4200204256 @default.
• W4297997373 cites W4205759188 @default.
• W4297997373 doi "https://doi.org/10.3389/fphar.2022.910656" @default.
• W4297997373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36249794" @default.
• W4297997373 hasPublicationYear "2022" @default.
• W4297997373 type Work @default.
• W4297997373 citedByCount "0" @default.
• W4297997373 crossrefType "journal-article" @default.
• W4297997373 hasAuthorship W4297997373A5006864304 @default.
• W4297997373 hasAuthorship W4297997373A5012929424 @default.
• W4297997373 hasAuthorship W4297997373A5024628268 @default.
• W4297997373 hasAuthorship W4297997373A5037377894 @default.
• W4297997373 hasAuthorship W4297997373A5079920224 @default.
• W4297997373 hasBestOaLocation W42979973731 @default.
• W4297997373 hasConcept C121608353 @default.
• W4297997373 hasConcept C126322002 @default.
• W4297997373 hasConcept C143998085 @default.
• W4297997373 hasConcept C187960798 @default.
• W4297997373 hasConcept C197934379 @default.
• W4297997373 hasConcept C207103383 @default.
• W4297997373 hasConcept C2775949291 @default.
• W4297997373 hasConcept C2776256026 @default.
• W4297997373 hasConcept C2777701055 @default.
• W4297997373 hasConcept C2780057760 @default.
• W4297997373 hasConcept C44249647 @default.
• W4297997373 hasConcept C71924100 @default.
• W4297997373 hasConcept C95190672 @default.
• W4297997373 hasConceptScore W4297997373C121608353 @default.
• W4297997373 hasConceptScore W4297997373C126322002 @default.
• W4297997373 hasConceptScore W4297997373C143998085 @default.
• W4297997373 hasConceptScore W4297997373C187960798 @default.
• W4297997373 hasConceptScore W4297997373C197934379 @default.
• W4297997373 hasConceptScore W4297997373C207103383 @default.
• W4297997373 hasConceptScore W4297997373C2775949291 @default.
• W4297997373 hasConceptScore W4297997373C2776256026 @default.
• W4297997373 hasConceptScore W4297997373C2777701055 @default.
• W4297997373 hasConceptScore W4297997373C2780057760 @default.
• W4297997373 hasConceptScore W4297997373C44249647 @default.
• W4297997373 hasConceptScore W4297997373C71924100 @default.
• W4297997373 hasConceptScore W4297997373C95190672 @default.
• W4297997373 hasFunder F4320321001 @default.
• W4297997373 hasLocation W42979973731 @default.
• W4297997373 hasLocation W42979973732 @default.
• W4297997373 hasLocation W42979973733 @default.
• W4297997373 hasOpenAccess W4297997373 @default.
• W4297997373 hasPrimaryLocation W42979973731 @default.
• W4297997373 hasRelatedWork W1900595920 @default.
• W4297997373 hasRelatedWork W1988490652 @default.
• W4297997373 hasRelatedWork W2194631636 @default.
• W4297997373 hasRelatedWork W2889691785 @default.

• next